Product fact sheet
Bio-K+ Advanced Bowel Support: Strains, AGA Guidance & Hospital Trial
Bio-K+ Advanced Bowel Support contains CL1285, LBC80R and CLR2 at 50 billion CFU per capsule, with AGA strain-level guidance and a later hospital effectiveness trial.
Bio-K+ discloses three proprietary strains and guarantees 50 billion CFU through expiration. Two of those strains—L. acidophilus CL1285 and L. casei LBC80R—appear together in AGA guidance for C. difficile prevention during antibiotic treatment. However, a later large hospital cluster-randomized trial of the three-strain Bio-K+ capsule did not significantly reduce hospital-acquired C. difficile infection.
People comparing probiotics with named strains and a direct professional-guideline connection, Readers who want both positive guidance and an important modern null study presented together
Anyone treating an active C. difficile infection with a supplement instead of medical care, Anyone assuming a guideline mention guarantees benefit in every hospital, baseline-risk setting or timing scenario
Key tradeoff: The product names its strains and guarantees CFU through expiration. Two strains appear in AGA guidance, while a later cluster-randomized hospital trial of the three-strain capsule did not significantly reduce hospital-acquired C. difficile infection.
This is a factual fit-and-tradeoff summary, not a product recommendation. Formula, device and brand claims remain manufacturer claims unless the cited source is explicitly regulatory or independent testing.
Bio-K+ Advanced Bowel Support Probiotic Capsules provide 50 billion CFU per capsule from three proprietary strains:
- Lactobacillus acidophilus CL1285;
- Lacticaseibacillus casei LBC80R;
- Lacticaseibacillus rhamnosus CLR2.
The manufacturer states that the 50-billion-CFU count is guaranteed through expiration when the product is stored as directed.
How the strains map to AGA guidance
The American Gastroenterological Association’s probiotic guideline names L. acidophilus CL1285 + L. casei LBC80R as one of several options it suggests for prevention of C. difficile infection in people receiving antibiotics.
That guidance applies to the named strain combination and clinical context. The current retail capsule also contains CLR2, so the finished product is not identical to the two-strain combination listed in the guideline.
What the hospital trial found
A later stepped-wedge cluster-randomized trial evaluated the three-strain Bio-K+ capsule program in hospitalized adults aged 55 and older. After adjustment, the intervention did not produce a statistically significant reduction in hospital-acquired C. difficile infection.
The result is relevant because it tested the current three-strain program in a real hospital setting. It also shows why guideline inclusion of a related strain combination should not be treated as proof that every implementation, population or endpoint will produce the same result.
Product formulation versus guideline formulation
The AGA-listed combination names CL1285 + LBC80R. The current Bio-K+ capsule contains those two strains plus CLR2.
Evidence for the two-strain combination should therefore remain separate from evidence for the three-strain finished product. The later hospital trial provides product-specific evidence for that distinction.
C. difficile symptoms need medical evaluation
Persistent or severe diarrhea after antibiotics—especially with fever, dehydration, significant abdominal pain or recent hospitalization—deserves medical evaluation. A probiotic is not a substitute for diagnostic testing and appropriate treatment of active C. difficile infection.
Main tradeoff
The product provides named strains and an expiration-date CFU guarantee, and two strains appear in AGA guidance. The important limitation is the later hospital trial, which did not show a statistically significant reduction in hospital-acquired C. difficile infection for the three-strain program.
Compare Florastor Dual Action for a strain-identified yeast option and Ther-Biotic ABx Support for an antibiotic-period blend whose current label does not disclose strain designations.
Formula facts
Ingredients, actives and label details
- Named strains
- Lacticaseibacillus casei LBC80R, Lacticaseibacillus rhamnosus CLR2, Lactobacillus acidophilus CL1285 Basis: Manufacturer Source: Bio-K+ Advanced Bowel Support Probiotic Capsules — official product information
- Viable count
- 50 billion CFU per capsule, guaranteed until expiration when stored as directed Basis: Manufacturer Source: Bio-K+ Advanced Bowel Support Probiotic Capsules — official product information
- Professional-guideline match
- AGA suggests the CL1285 + LBC80R two-strain combination as one option for C. difficile prevention in people receiving antibiotics Basis: Professional guideline Source: Role of probiotics in the management of gastrointestinal disorders
- Important negative evidence
- A stepped-wedge cluster-randomized trial in hospitalized adults age 55+ found no statistically significant adjusted reduction in hospital-acquired C. difficile infection with Bio-K+ Basis: Randomized trial Source: Effectiveness of Bio-K+ for the prevention of Clostridioides difficile infection: stepped-wedge cluster-randomized controlled trial
Source labels preserve provenance. Manufacturer specifications, ingredient lists and performance claims are not treated as independent clinical evidence; regulatory records and independent measurements are identified separately when available.
Safety first
What should make you slow down?
Use the product as directed, avoid treating concentrated wellness products as automatically harmless, and ask a qualified clinician when your situation or medication use makes the decision less routine.
Where to buy
Current tracked merchants
Commerce note: merchant economics never enter our editorial score. Affiliate links are identified as (paid link) and use sponsored-link markup.
No merchant destination is currently tracked for this product.
Source trail
Primary documents and supporting evidence
- Bio-K+ Advanced Bowel Support Probiotic Capsules — official product informationBio-K+ · Manufacturer · retrieved 2026-08-12
- Role of probiotics in the management of gastrointestinal disordersAmerican Gastroenterological Association · Clinical guideline · retrieved 2026-08-12
- Effectiveness of Bio-K+ for the prevention of Clostridioides difficile infection: stepped-wedge cluster-randomized controlled trialInfection Control & Hospital Epidemiology · Professional health · retrieved 2026-08-12